Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib plus Camrelizumab in Advanced Solid Tumors
NCT05429398Phase 1Unknown
- Sponsor
- Yingli Pharma
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of linperlisib in solid tumor, sponsored by Yingli Pharma. Primary endpoints: Dose Limiting Toxicities and Treatment Emergent Adverse Events. Status: unknown.
02
Drugs
linperlisib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05429398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429398.